Samsara BioCapital’s LENZ Therapeutics LENZ Stock Holding History

Samsara BioCapital’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-343,012	Closed	-$16M	–	30
2025 Q3	$16M	Hold	343,012	–	–	2.09%	9
2025 Q2	$10.1M	Sell	343,012 -183,378	-35%	-$4.99M	2.06%	9
2025 Q1	$13.5M	Sell	526,390 -460,591	-47%	-$11.3M	2.41%	9
2024 Q4	$28.5M	Sell	986,981 -221,492	-18%	-$6.75M	3.91%	7
2024 Q3	$28.7M	Hold	1,208,473	–	–	5.51%	7
2024 Q2	$20.9M	Hold	1,208,473	–	–	4.37%	8
2024 Q1	$27M	Hold	1,208,473	–	–	4.17%	7
2023 Q4	$22.2M	Hold	1,208,473	–	–	3.45%	7
2023 Q3	$21M	Hold	1,208,473	–	–	6.42%	6
2023 Q2	$22M	Hold	1,208,473	–	–	3.86%	5
2023 Q1	$20.7M	Hold	1,208,473	–	–	4.28%	5
2022 Q4	$28.1M	Hold	1,208,473	–	–	6.04%	4
2022 Q3	$26.8M	Hold	1,208,473	–	–	6.25%	4
2022 Q2	$23.3M	Buy	1,208,473 +55,244	+5%	+$1.23M	6.2%	4
2022 Q1	$41.2M	Buy	1,153,229 +31,524	+3%	+$1.97M	10.36%	2
2021 Q4	$97.6M	Buy	1,121,705 +60,045	+6%	+$4.97M	18.93%	1
2021 Q3	$122M	Hold	1,061,660	–	–	19.11%	1
2021 Q2	$228M	Buy	+1,061,660	New	+$185M	28.19%	1

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Samsara BioCapital's LENZ Position: Q4 2025 in Review

Samsara BioCapital sold out of LENZ Therapeutics (LENZ) in Q4 2025, closing a stake of 343,012 shares — an estimated $16M sold.

Samsara BioCapital first reported a position in LENZ in Q2 2021 and held it in 18 quarters. The position peaked at $228M in Q2 2021. 160 funds tracked by Wall St. Rank hold LENZ as of Q4 2025.

Samsara BioCapital reported no remaining LENZ Therapeutics position as of Q4 2025 after selling out during the quarter.
Samsara BioCapital sold 343,012 LENZ Therapeutics shares in Q4 2025, an estimated $16M.
Samsara BioCapital first reported a position in LENZ Therapeutics in Q2 2021 and held it in 18 quarters.
Samsara BioCapital's LENZ Therapeutics position peaked at $228M in Q2 2021.
160 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2025.

Based on Samsara BioCapital's 13F filing for Q4 2025, filed 17 Feb 2026.